Skip to main content

Apimeds Pharmaceuticals US, Inc.

APUS
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001894525

No open-market purchases or sales by Apimeds Pharmaceuticals US, Inc. insiders were filed in the last 90 days; 7 institutions reported holding it in 13F filings for Q2 2026, worth $383.7K in total; no superinvestor holds it.

Superinvestors holding APUS, Q2 2026

See all superinvestors

No superinvestor reported holding APUS in Q2 2026.